Values as of: 2025-01-11
COMMON STOCK | Biotechnology |
Last Closing
USD 21.005Change
0.00 (0.00)%Market Cap
USD 1.38BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. Further, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Company Website : https://www.genusplc.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 39.01B |
| UCBJF | UCB SA |
N/A |
USD 37.94B |
| UCBJY | UCB SA ADR |
N/A |
USD 37.34B |
| GNMSF | Genmab A/S |
N/A |
USD 13.64B |
| WXIBF | WuXi Biologics |
N/A |
USD 8.99B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 8.93B |
| IVBIY | IVBIY |
N/A |
USD 7.80B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.48B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 7.14B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 6.89B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | -25.01% | 51% | F | 36% | F | ||
| Dividend Return | 2.16% | 83% | B | 26% | F | ||
| Total Return | -22.85% | 52% | F | 36% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -46.14% | 69% | C- | 41% | F | ||
| Dividend Return | 4.76% | 20% | F | 12% | F | ||
| Total Return | -41.38% | 69% | C- | 40% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 4.41% | 50% | F | 45% | F | ||
| Dividend Return | 5.23% | 50% | F | 42% | F | ||
| Total Return | 0.82% | 46% | F | 25% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 61.59% | 61% | D- | 45% | F | ||
| Risk Adjusted Return | 8.48% | 55% | F | 41% | F | ||
| Market Capitalization | 1.38B | 91% | A- | 76% | C+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
